According to MRFR analysis, the global migraine drugs market is expected to register a CAGR of 5.9% during the forecast period of 2019 to 2025 and was valued at USD 4.4 billion in 2018.
Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8379
The growth of the global migraine drugs market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R&D investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for migraine are the factors that are expected to limit the growth of the global migraine drugs market during the forecast period.
The global migraine drugs market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. Migraine treatment drugs available are approved for the acute form of the condition, led by generic triptans as the first-line treatment. The global migraine treatment market is witnessing a rapid shift in terms of strong R&D with the launch of CGRP-based therapies and approval of novel drug classes such as ditans, gepants, and reformulation of triptans for the treatment of both chronic and episodic migraine. Launch of late-stage pipeline products such as erenumab, galcanezumab, fremanezumab, and eptinezumab by major players such as Eli Lilly and Company, Alder Pharmaceuticals, Inc., Teva Pharmaceuticals Ltd, and Amgen strengthened its market position in the global migraine drugs market in 2018.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R&D by major players in the region. For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults. It is the first drug to receive Food and Drug Administration (FDA) approval for decreasing the frequency of episodic cluster headache attacks. The migraine drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
The European migraine drugs market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The migraine drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Growing geriatric population, increasing patients suffering from neurological diseases, raising awareness about migraine, government initiatives in emerging economies to provide better healthcare infrastructure, and strategic initiatives by regional and market leaders are driving the migraine market in Asia-Pacific. The Asia-Pacific region is expected to be the fastest-growing during the forecast period.
The migraine drugs market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The global migraine drugs market has been segmented based on type, treatment, drug class, and end user.
The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.
The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.
The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.
The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.
Triptons are the most preferred type of drugs class for migraine patients due to its high efficacy. It holds the major share in the market by drug class. Approximately 80% of the migraine patients are treated with Triptans, and more than 40% of the patients suffering from cardiovascular diseases with migraine were treated with triptans in 2018.
The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others. The hospitals and clinics segment is expected to hold the largest share of the market as they are primary centers of treatment for the patient. The retail pharmacy segment offers over the counter (OTC) and prescription migraine drugs though a chain of pharmacies globally. Other end users include online pharmacy segment that offers OTC migraine drugs through e-commerce platforms.
Key Players
Some of the key players in the global migraine drugs market are Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca Plc (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc (US), Eli Lilly and Company, and eNeura Inc.
Access Report Details @ https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Have a Look at Related Reports:
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
